摘要
目的 :观察膦甲酸钠治疗伴有黄疸的慢性乙型肝炎和重型肝炎的疗效。方法 :治疗组80例 ,对照组42例 ,两组均给予综合治疗 ,治疗组另外加用膦甲酸钠2 4g 或3 0g,bid ,静脉滴注 ,疗程28d。结果 :HBeAg 阴转率治疗组为36 2 % ,对照组为11 8(P<0 025) ;HBV -DNA阴转率治疗组为26 6 % ,对照组为8 47 % (P<0 05) ;两组HBeAg及HBV -DNA未阴转者 ,治疗后其各自的半定量及定量检测水平 ,治疗组均显著地优于对照组 ;血清TBil复常率治疗组为27 5 % ,对照组为16 7 % (P<0 005) ;ALT、AST复常率治疗组分别为57 5 %、58 2 % ,对照组分别为23 8 %、19 1 % (P<0 005)。结论 :因膦甲酸钠具有抑制HBV复制及抑制免疫应答的作用 ,可用于治疗伴有黄疸的慢性乙型肝炎及重型肝炎。
OBJECTIVE:To observe the therapeutic effect of Foscarnet(PFA)on chronic hepatitis B combining jaundice and severe hepatitis B.METHODS:80cases were enrolled in the study group,42cases in the control group.Both groups received the same combined treatment.In addition,PFA was given in the study group,2.4or3.0g,b.i.d.for28days.RESULTS:The neg_ ative conversion rate of HBeAg in the study group was36.2%and it was11.8%in the control group(P<0.025).The negative conversion rate of HBV-DNA was26.6%in the study group and it was8.47%in the control group(P<0.05).The levels of the semi-quantitation and quantitation detection in the cases without negative conversion of HBeAg and HBV-DNA after treatment were much lower in study group than those in control group.Normalization rate of serum TBil in the study group was27.5%and it was16.7%in the control group(P<0.005).Normalization rates of ALT and AST in the study group were57.5%and58.2%and they were23.8%and19.1%in the control group respectively(P<0.005,P<0.005).CONCLUSION:Because of the inhibitive effect of PFA on both the HBV replication and the immune response,it could be used in the treatment of chronic hepatitis B combining jaundice and severe hepatitis B.
出处
《中国医院用药评价与分析》
2002年第1期33-34,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
